(More on Moderna here: https://www.keionline.org/moderna) KEI received a letter Dr. Gary Disbrow, the Acting Director of BARDA, just before noon today. BARDA2KEI.Moderna.Patent.Disclosures.20200903 The BARDA investigation follows the announcement on Saturday that DARPA was also investigating DARPA’s failures to disclose DARPA… Continue Reading
On September 2, 2020, Knowledge Ecology International (KEI) sent a letter to the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential failure by Moderna, Inc. to disclose federal funding in patents supported by BARDA. KEI requested information concerning… Continue Reading
(Update: The NIH has provided a response to our comments on August 31, 2020) On August 28, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) “Prospective… Continue Reading
(More on Moderna here: https://www.keionline.org/moderna) On August 28, 2020, KEI asked DARPA to investigate apparent failures to disclose U.S. government funding into Moderna’s patents and applications. The request, which was first covered by the Washington Post, and subsequently by Statnews,… Continue Reading
KEI Reports and Posts 2020. October 8. KEI on Moderna’s Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic. https://www.keionline.org/34112 2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding… Continue Reading
(More on Moderna here: https://www.keionline.org/moderna) Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies. One outcome… Continue Reading
(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading
On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading